Tag: Australia


Princeton, NJ—May 2, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today that it has published a new Global Health Care Systems Road Map—Australia Medical Devices.

Posted in Announcements, ISPOR News & Press Tagged with: , , , , , , ,


London, UK – Before a drug can be sold in Australia, it must receive approval from the regulator: the Therapeutic Goods Administration (TGA), typically requiring data from a large and lengthy Phase 3 randomized clinical trial. Public funding additionally requires

Posted in Health Policy Analyses Tagged with: , , ,

Communist Era Beliefs Are Constraining Privatisation Of Health In Poland

Brisbane, Australia – Research by the Chief Executive Officer of the Wesley Research Institute, Professor Christian Gericke, and a team of Polish academics led by Dr. Krzysztof Kaczmarek has found that while privatised health services are perceived in Poland to be

Posted in Value in Health Regional Issues Tagged with: , , ,

Issues And Challenges When Pharma Works With Regulators & HTA Agencies

Canberra, Australia – The pivotal phase III clinical trials for new medicines are designed to support their registration, yet they are also used to support their reimbursement and pricing. The clinical evidence needs of HTA agencies (payers) are often different than

Posted in Health Policy Analyses, Value in Health Tagged with: , , ,

Developing Countries Need To Produce Their Own Valuation Of Quality Of Life

Brisbane, Australia – Economic evaluations are essential to support efficient resource allocation in health care. This is of increased importance in developing countries with scarce resources and a high disease burden. To undertake economic evaluation, developing countries need to know the

Posted in Systematic Reviews, Value in Health Tagged with: , , , ,

Let’s Think for a Minute: Do Respondents Need Time to Deliberate When Undertaking Health State Valuation Exercises?

Perth, Western Australia – Increasingly, economic analyses are being used to make decisions on how to pay for new medicines and health care practices. Measuring and valuing quality of life are key components of economic analysis but, surprisingly, we know little

Posted in Preference-Based Assessments, Value in Health Tagged with: , ,

What Are The Important Factors In Selecting TCM?

Shenyang, China & Newcastle, Australia – The use of traditional Chinese medicine (TCM) has been gaining momentum in the past decades internationally. Even with quite a sizeable consumption and expenditure, there are still many barriers that prevent TCM to be reimbursed

Posted in Value in Health Regional Issues Tagged with: , , ,